secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bausch & Lomb Corp (BLCO)
CIK:        0001860742
Form:       8-K
Filed at:   2023-04-12T23:59:59+00:00
Accession:  0000950103-23-005621
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bausch + Lomb appoints new Chief Legal Officer and Ophthalmic Pharma President
------------------------------------------------------------------------------

- Christina Ackermann steps down as EVP & General Counsel and President, Ophthalmic Pharmaceuticals; departure effective April 28, 2023.
- Bob Bailey appointed EVP & Chief Legal Officer, effective April 24, 2023.
- Andrew Stewart appointed President, Ophthalmic Pharmaceuticals, effective April 24, 2023.
- Bailey previously served as CLO at Datavant and Allergan; Stewart joins from AbbVie eye care.
- Both Bailey and Stewart will join the executive management team.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860742/000095010323005621/0000950103-23-005621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860742/000095010323005621/dp192149_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-23-005621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer